High Efficacy of β-Blockers in Long-QT Syndrome Type 1 Contribution of Noncompliance and QT-Prolonging Drugs to the Occurrence of β-Blocker Treatment "Failures"

被引:210
作者
Vincent, G. Michael [1 ,2 ]
Schwartz, Peter J. [3 ,4 ,5 ,6 ]
Denjoy, Isabelle [7 ]
Swan, Heikki [8 ]
Bithell, Candice [1 ,2 ]
Spazzolini, Carla [3 ]
Crotti, Lia [3 ]
Piippo, Kirsi [9 ]
Lupoglazoff, Jean-Marc [10 ]
Villain, Elizabeth [11 ]
Priori, Silvia G. [4 ,12 ]
Napolitano, Carlo [12 ]
Zhang, Li [1 ,2 ]
机构
[1] LDS Hosp, Dept Med, Salt Lake City, UT USA
[2] Univ Utah, Salt Lake City, UT USA
[3] IRCCS Fdn Policlin S Matteo, Dept Cardiol, Pavia, Italy
[4] Univ Pavia, I-27100 Pavia, Italy
[5] IRCCS Inst Auxol, Lab Cardiovasc Genet, Milan, Italy
[6] Univ Cape Town, Dept Med, Hatter Inst Cardiovasc Res, Cardiovasc Genet Lab, ZA-7700 Rondebosch, South Africa
[7] Hop Lariboisiere, Serv Cardiol, F-75475 Paris, France
[8] Univ Helsinki, Dept Cardiol, Helsinki, Finland
[9] Univ Helsinki, Dept Med, Helsinki, Finland
[10] Hop Robert Debre, F-75019 Paris, France
[11] Hop Necker Enfants Malad, Paris, France
[12] IRCCS Fdn S Maugeri, Pavia, Italy
关键词
arrhythmia; death; sudden; heart arrest; long-QT syndrome; syncope; torsade de pointes; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; GENOTYPE-PHENOTYPE CORRELATION; SUDDEN CARDIAC DEATH; DE-POINTES; RISK; CHILDREN; THERAPY; GENDER; ARRHYTHMIAS; FREQUENCY;
D O I
10.1161/CIRCULATIONAHA.108.772533
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-beta-Blocker efficacy in long-QT syndrome type 1 is good but variably reported, and the causes of cardiac events despite beta-blocker therapy have not been ascertained. Methods and Results-This was a retrospective study of the details surrounding cardiac events in 216 genotyped long-QT syndrome type 1 patients treated with beta-blocker and followed up for a median time of 10 years. Before beta-blocker, cardiac events occurred in 157 patients (73%) at a median age of 9 years, with cardiac arrest (CA) in 26 (12%). QT-prolonging drugs were used by 17 patients; 9 of 17 (53%) had CA compared with 17 of 199 nonusers (8.5%; odds ratio, 12.0; 95% confidence interval, 4.1 to 35.3; P < 0.001). After beta-blocker, 75% were asymptomatic, and cardiac events were significantly reduced (P < 0.001), with a median event count (quartile 1 to 3) per person of 0 ( 0 to 1). Twelve patients (5.5%) suffered CA/sudden death, but 11 of 12 (92%) were noncompliant (n = 8), were on a QT-prolonging drug (n = 2), or both (n = 1) at the time of the event. The risk for CA/sudden death in compliant patients not taking QT-prolonging drugs was dramatically less compared with noncompliant patients on QT-prolonging drugs (odds ratio, 0.03; 95% confidence interval, 0.003 to 0.22; P = 0.001). None of the 26 patients with CA before beta-blocker had CA/sudden death on beta-blockers. Conclusions-beta-Blockers are extremely effective in long-QT syndrome type 1 and should be administered at diagnosis and ideally before the preteen years. beta-Blocker noncompliance and use of QT-prolonging drug are responsible for almost all life-threatening "beta-blocker failures." beta-Blockers are appropriate therapy for asymptomatic patients and those who have never had a CA or beta-blocker therapy. Routine implantation of cardiac defibrillators in such patients does not appear justified. (Circulation. 2009;119:215-221.)
引用
收藏
页码:215 / 221
页数:7
相关论文
共 31 条
[1]   Congenital long QT syndrome: Diagnosis and management in pediatric patients [J].
Bar-Cohen Y. ;
Silka M.J. .
Current Treatment Options in Cardiovascular Medicine, 2006, 8 (5) :387-395
[2]   β-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome [J].
Chatrath, R ;
Bell, CM ;
Ackerman, MJ .
PEDIATRIC CARDIOLOGY, 2004, 25 (05) :459-465
[3]   A systematic review of the associations between dose regimens and medication compliance [J].
Claxton, AJ ;
Cramer, J ;
Pierce, C .
CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310
[4]  
Crotti L, 2004, HEART RHYTHM, V1, pS82
[5]   Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients [J].
Curtis, LH ;
Ostbye, T ;
Sendersky, V ;
Hutchison, S ;
Lapointe, NMA ;
Al-Khatib, SM ;
Yasuda, SU ;
Dans, PE ;
Wright, A ;
Califf, RM ;
Woosley, RL ;
Schulman, KA .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (02) :135-141
[6]   THE EFFECT OF PRESCRIBED DAILY DOSE FREQUENCY ON PATIENT MEDICATION COMPLIANCE [J].
EISEN, SA ;
MILLER, DK ;
WOODWARD, RS ;
SPITZNAGEL, E ;
PRZYBECK, TR .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (09) :1881-1884
[7]   Long QT syndrome in children in the era of implantable defibrillators [J].
Etheridge, Susan P. ;
Sanatani, Shubhayan ;
Cohen, Mitchell I. ;
Albaro, Cecilia A. ;
Saarel, Elizabeth V. ;
Bradley, David J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (14) :1335-1340
[8]   Implantable cardioverter defibrillator therapy in children with long QT syndrome [J].
Goel, AK ;
Berger, S ;
Pelech, A ;
Dhala, A .
PEDIATRIC CARDIOLOGY, 2004, 25 (04) :370-378
[9]   Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome [J].
Hobbs, Jenny B. ;
Peterson, Derick R. ;
Moss, Arthur J. ;
McNitt, Scott ;
Zareba, Wojciech ;
Goldenberg, Ilan ;
Qi, Ming ;
Robinson, Jennifer L. ;
Sauer, Andrew J. ;
Ackerman, Michael J. ;
Benhorin, Jesaia ;
Kaufman, Elizabeth S. ;
Locati, Emanuela H. ;
Napolitano, Carlo ;
Priori, Silvia G. ;
Towbin, Jeffrey A. ;
Vincent, G. Michael ;
Zhang, Li .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (10) :1249-1254
[10]   CONGENITAL DEAF-MUTISM, FUNCTIONAL HEART DISEASE WITH PROLONGATION OF THE Q-T INTERVAL, AND SUDDEN DEATH [J].
JERVELL, A ;
LANGENIELSEN, F .
AMERICAN HEART JOURNAL, 1957, 54 (01) :59-68